CMPX Q3 2024 Earnings — Compass Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CMPXCompass Therapeutics, Inc.

$781M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$12M

Net Income

-$10M

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$149M

Total Liabilities

$11M

Stockholders' Equity

$138M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$12M	-$12M	-2.6%
Net Income	-$10M	-$10M	-5.2%